PARP Inhibitors Market Size, Share, Analysis, Trends, Growth, 2032

PARP Inhibitors Industry Prospective:

The global PARP inhibitors market size was worth around USD 3.19 billion in 2023 and is predicted to grow to around USD 8.62 billion by 2032 with a compound annual growth rate (CAGR) of roughly 11.70% between 2024 and 2032.

Request Free Sample

PARP Inhibitors Market: Overview

P-ADP ribose polymerase (PARP) inhibitors are a class of targeted therapy for cancer. They are used for treating several types of cancer including prostate cancer, breast cancer, ovarian cancer, and others. The most common types of PARP inhibitors include talazoparib, rucaparib, niraparib, and olaparib. PARP is a type of enzyme or protein found in cells. They help in repairing damaged cells in the body. As a form of cancer treatment, PARP inhibitors restrict the enzyme from performing their functions in repairing cancer cells allowing them to die with time.

Initially, researchers used the drug for treating cancer that had problems in repairing cell damage. The main focus was on treating cancers with a gene mutation called Breast Cancer gene (BRCA). Science suggests that people with faulty BRCA genes are at a higher risk of certain types of cancers including prostate, ovarian, and breast cancers. Extensive research has indicated that the treatment method can be used for cancers that have shown cell weaknesses mimicking the BRCA gene fault.

Thus, the ongoing research to learn about the impact of PARP inhibitors on kidney cancer, lung cancer, head & neck cancer, pancreatic cancer, and others is expected to generate growth opportunities in the industry. The high cost of treatment and limited availability can impact the overall revenue during the forecast period.

Key Insights:

• As per the analysis shared by our research analyst, the global PARP inhibitors market is estimated to grow annually at a CAGR of around 11.70% over the forecast period (2024-2032)
• In terms of revenue, the global PARP inhibitors market size was valued at around USD 3.19 billion in 2023 and is projected to reach USD 8.62 billion by 2032.
• The market is projected to grow at a significant rate due to the Growing number of breast and ovarian cancer cases.
• Based on the indication, the breast cancer segment is growing at a high rate and will continue to dominate the global market as per industry projection
• Based on the distribution channels, the hospital pharmacies segment is anticipated to command the largest market share.
• Based on region, North America is projected to dominate the global market during the forecast period.

PARP Inhibitors Market: Growth Drivers

Growing number of breast and ovarian cancer cases to drive market demand rate in the coming years

The global PARP inhibitors market is expected to generate growth opportunities due to the rising cases of breast and ovarian cancer. The women population is vulnerable to these cancers. For instance, breast cancer starts in the breast region and it can occur in men too. Studies indicate that most breast lumps are benign and non-life-threatening. However, in certain cases, benign breast lumps can increase the chances of breast cancer in women. There are different types of breast cancers and the most common form is carcinomas.

According to the World Center Research Fund International, breast cancer is the second most common type of cancer reported worldwide. In women, it is the number one form of the disease. In 2022, over 2,296,840 new cases of breast cancer were reported.

On the other hand, ovarian cancer is also reported among the female population. It results from abnormal growth of cells in the ovaries. Some of the most common signs of ovarian cancer include weight loss, discomfort in the pelvic region, abdominal swelling or bloating, back pain, fatigue, and a frequent need to urinate. The reasons for ovarian cancer are unknown but certain risk factors include obesity, family history of ovarian cancer, older age, postmenopausal hormone replacement therapy, and endometriosis.

Ongoing development of new cancer treatment and research facilities to aid further revenue generation

Due to the wide-scale prevalence of cancer, the demand for effective and robust research and treatment infrastructure is on the rise. The growing development of new cancer care centers along with digitization of the cancer medical care segment will directly contribute to the demand in the global PARP inhibitors market.

In addition to this, market studies indicate that the integration of advanced imaging tools along with artificial intelligence (AI) technologies will aid further enhancements in personalized cancer treatment.

PARP Inhibitors Market: Restraints

High cost of treatment and limited treatment availability limit the industry's expansion rate

The global industry for PARP inhibitors is projected to be restricted by the high cost of the treatment. According to market analysis, the average cost of PARP treatment can reach up to USD 20000 per month. In addition to this, the cost increases further in the absence of medical insurance policies or efficient healthcare plans.

The treatment remains unaffordable for a large number of patients, especially in lower or middle-income groups. The limited availability of medical professionals with expertise in PARP inhibitors-based treatment further restricts the overall expansion in the market.

PARP Inhibitors Market: Opportunities

Ongoing research & development in the industry to generate massive growth opportunities

The global PARP inhibitors market is projected to generate growth opportunities due to the ongoing research & development in the industry. PARP inhibitors are a form of targeted therapy and have witnessed significant applications in the last decade. In April 2024, the American Association for Cancer Research published a report highlighting the impact of Saruparib in cancer treatment. According to the agency, this selective inhibitor for PARP1 had shown promising results in the treatment of patients with homologous recombination repair (HRR)-deficient breast cancers in the phase I/II PETRA trial.

Moreover, the increasing investments in research of next-generation PARP inhibitors are likely to open new avenues for further growth. A recent study conducted by the Columbia University - Irving Medical Center reported that studies suggested novel ways of improving treatment for breast cancer with hereditary background. The research team recommends a combination of axitinib with PARP inhibitors which will improve the responsiveness of cancer cells to the treatment. Researchers are working toward reducing the cases of cancer relapse after the patients have undergone PARP inhibitor treatment.

PARP Inhibitors Market: Challenges

Regulatory complexities and higher cases of cancer coming back a major challenge for the industry players

The global industry for PARP inhibitors is challenged by the intense regulatory complexities associated with the development and application of cancer drugs. At present, only a limited number of PARP inhibitor drugs are approved by the US Food & Drugs Administration. In addition to this, the growing cases of cancer relapse post PARP inhibitor treatment are further impacting overall growth in the industry.

PARP Inhibitors Market: Report Scope

PARP Inhibitors Market: Segmentation

The global PARP inhibitors market is segmented based on indication, drug type, distribution channel, and region.

Based on the indication, the global market segments are prostate cancer, breast cancer, pancreatic cancer, and ovarian cancer. In 2023, the highest growth was listed in the breast cancer segment. The rising cases of cancer emerging in the breast area have led to increased segmental revenue. Furthermore, research based on breast cancer treatment has received major investments in the last few years which could help the segment thrive in the coming years. As per the American Cancer Society, an average US woman has a 13% chance of developing breast cancer at some point in her life.

Based on drug type, the global PARP inhibitors industry is divided into rucaparib, niraparib, olaparib, and talazoparib.

Based on the distribution channels, the global market divisions are online pharmacies, retail pharmacies, and hospital pharmacies. In 2023, the highest demand was listed in the hospital pharmacies segment. The increasing rate of patient footfall at hospitals for the treatment of cancer is pivotal to segmental demand. Retail pharmacies are registering high growth due to the adoption of digital systems for improved customer care and online delivery of prescription-based medicines. CVS Pharmacy has more than 9000 stores across the US as of 2024.

PARP Inhibitors Market: Regional Analysis

North America to deliver optimal results during the projection period

The global PARP inhibitors market is expected to be led by North America during the forecast period. The US is projected to emerge as the leading player in the region. For instance, the presence of research-based and highly innovative cancer care infrastructure in the US helps the region attract domestic and international patients seeking optimal care and treatment against cancer.

In October 2024, US-based pharmaceutical giant Pfizer announced promising results from the last prespecified overall survival (OS) analysis of the TALAPRO-2 study concerning an oral PARP inhibitor TALZENNA® in combination with XTANDI. The latter is an androgen receptor pathway inhibitor (ARPI). The results have shown promising responses for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Europe has shown promising signs of growth in the future.

In September 2024, researchers from the University of Bern and the University of Lausanne, Switzerland, launched the VirtualMultiplexer. It is a novel AI-driven imaging tool equipped to convert histology images into cancer layers thus allowing faster and more accurate diagnosis of the disease.

PARP Inhibitors Market: Competitive Analysis

The global PARP inhibitors market is led by players like:

• Johnson & Johnson (via Janssen)
• AstraZeneca
• Zentalis Pharmaceuticals
• Jiangsu Hengrui Pharmaceuticals
• GSK (GlaxoSmithKline)
• Repare Therapeutics
• Clovis Oncology
• EMD Serono (Merck KGaA)
• Merck & Co.
• Bristol-Myers Squibb
• AbbVie
• Pfizer
• Novartis
• Bayer
• BeiGene.

The global PARP inhibitors market is segmented as follows:

By Indication

• Prostate Cancer
• Breast Cancer
• Pancreatic Cancer
• Ovarian Cancer

By Drug Type

• Rucarib
• Niraparib
• Olaparib
• Talazoparib

By Distribution Channel

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa